Paclitaxel (PTX) remains a cornerstone in the treatment
of locally
advanced and metastatic lung cancer. To improve its therapeutic indices
against lung cancer, novel redox-sensitive pullulan/PTX-based prodrug
NPs (PULL–SS–PTX NPs) were accomplished, which were
further surface-decorated with transferrin (TF), a cancer cell-targeting
ligand, to afford TF–PULL–SS–PTX NPs. These prodrug
NPs (drug content, >37% and average size, 134–163 nm) rapidly
dismantled their self-assembled architecture upon exposure to simulated
reducing conditions, causing a triggered drug release as compared
to the control scaffold (PULL–CC–PTX NPs). These scaffolds
also evidenced outstanding colloidal stability, cellular uptake efficiency,
and discriminating cytotoxicity between the cancer and healthy cells.
Intravenously delivered redox-sensitive NPs exhibited improved tumor-suppressing
properties as compared to the control nanovesicles (PULL–CC–PTX
NPs) in a B16–F10 melanoma lung metastasis mice model. The
targeting efficiency and associated augmented anticancer potentials
of TF–PULL–SS–PTX NPs relative to TF-free redox-responsive
NPs and Taxol intravenous injection were also established on the transferrin
receptor (TFR) overexpressed Lewis lung carcinoma (LLC–luc)
cell-bearing mice model. Moreover, the TF-functionalized scaffold
displayed a reduced systemic toxicity compared to that of Taxol intravenous
injection. Overall, the proposed TF-decorated prodrug NPs could be
a promising nanomedicine for intracellular PTX delivery against metastatic
lung cancer.